Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 48, 2016, Pages E7769-E7777

  Danilova, Ludmila ^a,b   Wang, Hao ^a   Sunshine, Joel ^a   Kaunitz, Genevieve J ^a   Cottrell, Tricia R ^a   Xu, Haiying ^a   Esandrio, Jessica ^a   Anders, Robert A ^a   Cope, Leslie ^a   Pardoll, Drew M ^a   Drake, Charles G ^a   Taube, Janis M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VAVILOV INSTITUTE OF GENERAL GENETICS   (Russian Federation)

Author keywords

Melanoma; Mutational load; PD 1; PD L1; PD L2

Indexed keywords

CD8 ANTIGEN; MESSENGER RNA; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; TH1/IFNG; TUMOR MARKER; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; PDCD1LG2 PROTEIN, HUMAN;

ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; CYTOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; MELANOMA; MUTATIONAL LOAD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR MICROENVIRONMENT; ADENOCARCINOMA; COLON TUMOR; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; MUTATION; MUTATION RATE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SKIN TUMOR;

ADENOCARCINOMA; B7-H1 ANTIGEN; COLONIC NEOPLASMS; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; MELANOMA; MUTATION; MUTATION RATE; PROGNOSIS; PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN; PROGRAMMED CELL DEATH 1 RECEPTOR; PROPORTIONAL HAZARDS MODELS; SKIN NEOPLASMS;

EID: 84999142201     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1607836113     Document Type: Article

References (101)

1. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144(5):646-674.
2. Lennerz V, et al. (2005) The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci USA 102(44):16013-16018.
3. Matsushita H, et al. (2012) Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482(7385):400-404.
4. Robbins PF, et al. (2013) Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19(6):747-752.
5. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N (2015) Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160(1-2):48-61.
6. Taube JM, et al. (2012) Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4(127):127ra37.
7. Robert C, et al. (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320-330.
8. Tumeh PC, et al. (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568-571.
9. Brahmer J, et al. (2014) Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis. J Clin Oncol 32:8112 (abstr).
10. Fridman WH, Pagès F, Sautès-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12(4):298-306.
11. Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360(8):790-800.
12. Halama N, et al. (2011) Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res 71(17):5670-5677.
13. Denkert C, et al. (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28(1):105-113.
14. Brown SD, et al. (2014) Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res 24(5):743-750.
15. Rizvi NA, et al. (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230):124-128.
16. Topalian SL, et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443-2454.
17. Taube JM, et al. (2014) Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20(19):5064-5074.
18. Herbst RS, et al. (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528):563-567.
19. Sunshine J, Taube JM (2015) PD-1/PD-L1 inhibitors. Curr Opin Pharmacol 23:32-38.
20. Wu C, et al. (2006) Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 108(1):19-24.
21. Ohigashi Y, et al. (2005) Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 11(8):2947-2953.
22. Thompson RH, et al. (2006) Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66(7):3381-3385.
23. Hamanishi J, et al. (2007) Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 104(9):3360-3365.
24. Nomi T, et al. (2007) Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 13(7):2151-2157.
25. Giraldo NA, et al. (2015) Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin Cancer Res 21(13):3031-3040.
26. Lipson EJ, et al. (2013) PD-L1 expression in the Merkel cell carcinoma microenvironment: Association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res 1(1):54-63.
27. Wimberly H, et al. (2015) PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. Cancer Immunol Res 3(4):326-332.
28. Karim R, et al. (2009) Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res 15(20):6341-6347.
29. Hino R, et al. (2010) Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 116(7):1757-1766.
30. Velcheti V, et al. (2014) Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 94(1):107-116.
31. Wang A, et al. (2015) The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis. Eur J Surg Oncol 41(4):450-456.
32. Zhang Y, et al. (2014) Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco Targets Ther 7:567-573.
33. Shi M, et al. (2014) Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. Am J Surg Pathol 38(12):1715-1723.
34. Thompson RH, et al. (2007) PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 13(6):1757-1761.
35. Ngiow SF, et al. (2015) A threshold level of intratumor CD8+ T-cell PD1 expression dictates therapeutic response to anti-PD1. Cancer Res 75(18):3800-3811.
36. Parsa AT, et al. (2007) Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13(1):84-88.
37. Green MR, et al. (2010) Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116(17):3268-3277.
38. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252-264.
39. Skoulidis F, et al. (2015) Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov 5(8):860-877.
40. Lawrence MS, et al. (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499(7457):214-218.
41. Badoual C, et al. (2013) PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 73(1):128-138.
42. Shain AH, et al. (2015) Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nat Genet 47(10):1194-1199.
43. Busam KJ, et al. (2004) Cutaneous desmoplastic melanoma: Reappraisal of morphologic heterogeneity and prognostic factors. Am J Surg Pathol 28(11):1518-1525.
44. Gubin MM, Schreiber RD (2015) CANCER. The odds of immunotherapy success. Science 350(6257):158-159.
45. Taube JM, et al. (2015) Differential expression of immune-regulatory genes associated with PD-L1 display in melanoma: Implications for PD-1 pathway blockade. Clin Cancer Res 21(17):3969-3976.
46. Peng W, et al. (2016) Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov 6(2):202-216.
47. Ascierto PA, et al. (2013) MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 14(3):249-256.
48. Brahmer J, et al. (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123-135.
49. Motzer RJ, et al. (2015) Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial. J Clin Oncol 33(13):1430-1437.
50. Motzer RJ, et al.; CheckMate 025 Investigators (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803-1813.
51. McDermott DF, et al. (2016) Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: Long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol 34(8):833-842.
52. Higgs BW, et al. (2015) High tumoral IFNg mRNA, PD-L1 protein, and combined IFNg mRNA/PD-L1 protein expression associates with response to durvalumab (anti-PD-L1) monotherapy in NSCLC patients. European Cancer Conference 2015 (European Cancer Congress, Vienna), abstr 15LBA.
53. Woo SR, et al. (2012) Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 72(4):917-927.
54. + T cells in melanoma patients. J Clin Invest 125(5):2046-2058.
55. Spranger S, et al. (2014) Mechanism of tumor rejection with doublets of CTLA-4, PD-1/ PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer 2:3.
56. Ding H, et al. (2006) Delivering PD-1 inhibitory signal concomitant with blocking ICOS co-stimulation suppresses lupus-like syndrome in autoimmune BXSB mice. Clin Immunol 118(2-3):258-267.
57. Sakuishi K, et al. (2010) Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 207(10):2187-2194.
58. Melero I, Grimaldi AM, Perez-Gracia JL, Ascierto PA (2013) Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res 19(5):997-1008.
59. Koyama S, et al. (2016) Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun 7:10501.
60. Buchan SL, et al. (2015) OX40- and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ T cells to exit quiescence. J Immunol 194(1):125-133.
61. Melero I, et al. (2015) Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer 15(8):457-472.
62. Yi KH, Chen L (2009) Fine tuning the immune response through B7-H3 and B7-H4. Immunol Rev 229(1):145-151.
63. Crispen PL, et al. (2008) Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res 14(16):5150-5157.
64. Roth TJ, et al. (2007) B7-H3 ligand expression by prostate cancer: A novel marker of prognosis and potential target for therapy. Cancer Res 67(16):7893-7900.
65. Wang J, et al. (2013) B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma. J Invest Dermatol 133(8):2050-2058.
66. Mao Y, et al. (2015) B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer. Oncotarget 6(5):3452-3461.
67. Xu H, et al. (2016) B7-H3 and B7-H4 are independent predictors of a poor prognosis in patients with pancreatic cancer. Oncol Lett 11(3):1841-1846.
68. Leitner J, et al. (2009) B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction. Eur J Immunol 39(7):1754-1764.
69. Powderly J, et al. (2015) Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3. J Immunother Cancer 3(Suppl 2):O8.
70. Nakano O, et al. (2001) Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 61(13):5132-5136.
71. Beuselinck B, et al. (2015) Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. Clin Cancer Res 21(6):1329-1339.
72. Remark R, et al. (2013) Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res 19(15):4079-4091.
73. Schalper KA, et al. (2014) In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res 20(10):2773-2782.
74. Cooper WA, et al. (2015) PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer 89(2):181-188.
75. Senbabaoglu Y, et al. (September 1, 2015) The landscape of T cell infiltration in human cancer and its association with antigen presenting gene expression. bioRxiv, 10.1101/025908.
76. Bindea G, et al. (2013) Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39(4):782-795.
77. Le DT, et al. (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372(26):2509-2520.
78. Van Allen EM, et al. (2015) Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350(6257):207-211.
79. Snyder A, et al. (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371(23):2189-2199.
80. Gajewski TF, Schreiber H, Fu YX (2013) Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14(10):1014-1022.
81. Kluger HM, et al. (2015) Characterization of PD-L1 expression and associated T-cell infiltrates in metastatic melanoma samples from variable anatomic sites. Clin Cancer Res 21(13):3052-3060.
82. Cancer Genome Atlas Research Network (2013) Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499(7456):43-49.
83. Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507(7492):315-322.
84. Cancer Genome Atlas Research Network (2014) Comprehensive molecular profiling of lung adenocarcinoma. Nature 511(7511):543-550.
85. Cancer Genome Atlas Research Network (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489(7417):519-525.
86. Cancer Genome Atlas Network (2015) Genomic classification of cutaneous melanoma. Cell 161(7):1681-1696.
87. Cancer Genome Atlas Network (2015) Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517(7536):576-582.
88. Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61-70.
89. Cancer Genome Atlas Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487(7407):330-337.
90. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Roy Stat Soc B Met 57(1):289-300.
91. R Core Team (2004) R: A Language and Environment for Statistical Computing. (R Foundation for Statistical Computing, Vienna, Austria). Available at https://www.r-project.org/. Accessed May 6, 2015.
92. Smyth G (2005) Limma: Linear models for microarray data. Bioinformatics and Computational Biology Solutions using R and Bioconductor, eds Gentleman R, Carey VJ, Dudoit S, Irizarry R, Huber W (Springer, New York), pp 397-420.
93. Andersen PK, Gill RD (1982) Cox's regression model for counting processes: A large sample study. Ann Stat 10(4):1100-1120.
94. Therneau TM, Grambsch PM (2000) Modeling Survival Data: Extending the Cox Model (Springer, New York), 1st Ed.
95. Hothorn T, Hornik K, Zeileis A (2006) Unbiased recursive partitioning: A conditional inference framework. J Comput Graph Stat 15(3):651-674.
96. Hothorn T, Zeileis A (2015) partykit: A modular toolkit for recursive partytitioning in R. J Mach Learn Res 16:3905-3909.
97. Gentleman RC, et al. (2004) Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol 5(10):R80.
98. Hanson BA (2014) The HiveR Package.1-23. Available at academic.depauw.edu/~hanson/HiveR/HiveR.html. Accessed May 6, 2015.
99. Lumley T (2012) rmeta: Meta-analysis. R package version. Available at CRAN.R-project.org/package=rmeta. Accessed May 6, 2015.
100. Gao J, et al. (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6(269):pl1.
101. Cerami E, et al. (2012) The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2(5):401-404.